Submissions from 2023
RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non-small cell lung cancer (NSCLC), Joshua E. Reuss, Sunil G. Gandhi, David R. Spigel, Pasi A. Janne, Luis G. Paz-Ares, Shirish M. Gadgeel, Jyoti D. Patel, Francesco Passiglia, Alexander I. Spira, Martin J. Edelman, George R. Blumenschein, Ardaman Shergill, Timothy F. Burns, Vijeta Bhambhani, Gloria Patrick, Jonathan A. Pachter, Louis J. Denis, and D Ross Camidge
Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study, Dan-yun Ruan, Myung A. Lee, Yanhong Deng, Keun-Wook Lee, Michael Millward, Jaspreet S. Grewal, Shirish M. Gadgeel, Rachel E. Sanborn, Xinfang Hou, Shaozhong Wei, Seok J. Huh, Fu-Rong Liu, Xiaoxi Xie, Ziyong Xiang, Zhe Shi, Yaolin Wang, Ling Zhang, Gary E. Richardson, and Rui-Hua Xu
Expression of lysine demethylase 5a (Kdm5a) influences tumour aggressiveness in murine pancreatic cancer cells, Nicole Schreiner, Lisa Fahr, Simone Benitz, Quan Zhou, Ahmed Alnatsha, Axel Imhof, Ujjwal Mahajan, Julia Mayerle, and Ivonne Regel
Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors, Aditi Shastri, Eric J. Feldman, Alexander N. Starodub, Tatyana Feldman, Cristina P. Rodriguez, Zachary D. Epstein-Peterson, Don A. Stevens, Adam J. Olszewski, Auris O. Huen, Pierluigi Porcu, John C. Reneau, Stefan K. Barta, Enrica Marchi, Ahmad H. Mattour, Lauren C. Pinter-Brown, Rachelle Perea, Sean Donohue, Joyoti Dey, Sagar Agarwal, Rahul Karnik, Ashwin Gollerkeri, Jared Gollob, and Stephen D. Smith
SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers, Rachna T. Shroff, Katherine A. Guthrie, Aaron J. Scott, Mitesh J. Borad, Laura W. Goff, Khalid Matin, Amit Mahipal, Aparna Kalyan, Milind M. Javle, Carol Aghajanian, Benjamin R. Tan, Puneet S. Cheema, Anuj K. Patel, Renuka V. Iyer, Robin K. Kelley, Jaykumar R. Thumar, Anthony B. El-Khoueiry, E. Gabriela Chiorean, Howard S. Hochster, and Philip A. Philip
OA10.03 Assessing Availability and Demand for Patient-Friendly Resources in Lung Cancer Care: The Patient Perspective, E. K. Singh, A. Desai, Fawzi Abu Rous, and J. Feldman
Preliminary Analysis of ATHN 16: Real-World Safety of Eptacog Beta, T. Singleton, S. Acharya, S. Ahuja, L. Amos, D. Bonzo, A. Eason, M. Escobar, C. Knoll, Philip Kuriakose, E. Lagrue, M. Recht, S. Sullivan, D. Quon, and M. Reding
False positive PET scan in patients with treated malignancy following COVID-19 vaccination, Alexander A. Slota, Vrajesh Parmar, Amy M. Weise, and Ding Wang
2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC), S Sridhar, P. H. O'Donnell, T. W. Flaig, J. E. Rosenberg, C. J. Hoimes, M. I. Milowsky, S. Srinivas, S. George, R. R. McKay, D. P. Petrylak, P. M. Coelho Barata, Clara Hwang, M. Cruz-Correa, M. Iafolla, M Mckean, R Dreicer, S Brancato, J. J. Lukas, Y Yu, and H Moon
Polygenic risk scores in assessing lung cancer susceptibility in non-Hispanic White and Black populations, Matthew R. Trendowski, Chrissy Lusk, Angie Wenzlaff, Christine Neslund-Dudas, Shirish M. Gadgeel, Ayman Soubani, and Ann G. Schwartz
Preliminary results from ERAS-007 plus palbociclib (palbo) in patients (pts) with KRAS/ NRAS mutant (m) colorectal cancer (CRC) or KRASm pancreatic ductal adenocarcinoma (PDAC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogenactivated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers), Susanna V. Ulahannan, David R. Spigel, Michael S. Lee, Marwan Fakih, Patrick Grierson, Eric Christenson, E. Gabriela Chiorean, Darryl A. Outlaw, Gazala Khan, Chloe E. Atreya, Aparna R. Parikh, Farshid Dayyani, Alexander I. Spira, Scott Kopetz, Andrea J. Bullock, Zhengrong Li, Xiaoying Chen, Hina Patel, Saswati Hazra, and John H. Strickler
Does Implementing Calendars Outlining Inpatient Chemotherapy Schedules in Patient Rooms Improve Patient's Experience?, Kashmira Wani and Vrushali S. Dabak
Comparison of Maintenance Therapy Regimens of Patients Treated for Multiple Myeloma, Kashmira Wani, Radhika Gutta, Aayush Mittal, Maria Jamil, Kylie Springer, and Philip Kuriakose
Impact of Race on Progression-Free Survival and Overall Survival in Patients with Multiple Myeloma, Kashmira Wani, Radhika Gutta, Aayush Mittal, Maria Jamil, Kylie Springer, and Philip Kuriakose
A phase II trial of pevonedistat plus docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC), Leah Wells, Angel Qin, John Rice, Shirish M. Gadgeel, Bryan J. Schneider, Nithya Ramnath, Lili Zhao, and Gregory P. Kalemkerian
Modeling Risk of Atrial Fibrillation in Stem Cell Transplant, Min Wu, Rayli Pichardo, Sowjanya Vuyyala, Josephine Emole, Edward Peres, Muneer H. Abidi, Madhulata Reddy, and Shatha Farhan
Submissions from 2022
Racial and gender disparities in next-generation sequencing for pancreatic adenocarcinoma, Fawzi Abu Rous, Sunny R. K Singh, Chun-Hui Lin, Laila M. Poisson, and Gazala Khan
(P44) Is Prophylactic Cranial Irradiation Necessary in Stage I-IIA Small Cell Lung Cancer Patients? A Single Institution Experience, Sondos Alkhatib, Aharon Feldman, Shirish M. Gadgeel, Andrew Popoff, Munther Ajlouni, Michael Simoff, and Benjamin Movsas
1544P Pre-treatment CT radiomics predicts survival in chemo-immunotherapy-treated small cell lung cancer, Joseph Bae, Prateek Prasanna, and Shirish M. Gadgeel
An Unsupervised Autoencoder Developed from Dynamic Contrast-Enhanced (DCE)-MRI Datasets for Classification of Acute Tumor Response in an Animal Model, Hassan Bagher-Ebadian, Tavarekere N. Nagaraja, Glauber Cabral, Katelynn G. Farmer, Olivia Valadie, P. Acharya, Benjamin Movsas, Stephen L. Brown, Indrin J. Chetty, and James R. Ewing
Association of immunotherapy and immunosuppression with severe COVID-19 disease in patients with cancer, Z. Bakouny, P. Grover, C. Labaki, J. Awosika, S. Gulati, C. Y. Hsu, M. A. Bilen, O. Eton, L. Fecher, Clara Hwang, H. Khan, R. R. McKay, E. Ruiz, L. Weissmann, M. A. Thompson, D. Shah, J. Warner, Y. Shyr, T. K. Choueiri, and T. Wise-Draper
KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRAS mutation, Tanios S. Bekaii-Saab, Alexander I. Spira, Rona Yaeger, Gary L. Buchschacher, Autumn Jackson McRee, Joshua K. Sabari, Melissa L. Johnson, Minal A. Barve, Navid Hafez, Karen Velastegui, James G. Christensen, Thian Kheoh, Hirak Der-Torossian, and Igor I. Rybkin
Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase I/II ARROS-1 study, B. Besse, M. Johnson, S. H. I. Ou, Shirish M. Gadgeel, A. Spira, J. Lin, E. Felip, A. J. van der Wekken, A. Calles, M. J. de Miguel, D. R. Camidge, Y. Elamin, G. D. L. Lopes, S. Liu, J. Bauman, D. Haggstrom, G. Riley, H. E. Pelish, V. W. Zhu, and A. Drilon
Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors, A. Drilon, B. Besse, D. R. Camidge, S. H. I Ou, Shirish M. Gadgeel, M. L. Johnson, A. Calles, M. J. de Miguel, A. I. Spira, E. Felip, G. Lopes, A. J. van der Wekken, Y. Y. Elamin, J. Green, Y. Sun, J. Soglia, V. W. Zhu, and J. J. Lin
EP08.02-041 NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study, A. Drilon, S. H.I Ou, Shirish M. Gadgeel, M. Johnson, A. Spira, G. Lopes, B. Besse, E. Felip, A. J. van der Wekken, A. Calles, M. J. de Miguel, D. R. Camidge, Y. Elamin, S. Liu, J. Bauman, D. Haggstrom, G. Riley, H. E. Pelish, V. W. Zhu, and J. J. Lin
Does contralateral prophylactic mastectomy improve survival in triple negative breast cancer?, Genevieve A. Fasano, Solange Bayard, Yalei Chen, Jennifer Marti, Rache Simmons, Alexander Swistel, Jessica Bensenhaver, S. David Nathanson, Lindsay Petersen, Erica Proctor, Melissa Davis, and Lisa Newman
1549TiP DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE®), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC), Shirish M. Gadgeel, J. Al-Mondhiry, M. J. Ahn, S. W. Kim, L. Paz-Ares, H. Prenen, M. Boyer, J. G. Bustamanta Alvarez, B. Solomon, S. Huang, M. Minocha, M. Kistler, and N. Hashemi Sadraei
Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I/II ARROW study and real-world data (RWD), Shirish M. Gadgeel, J. Gainor, F. Cappuzzo, E. Garralda, D. H. Lee, J. Mazieres, D. W. Kim, V. Zhu, G. Lopes, S. Miller, M. Nowicka, H. Trinh, S. M. Arndorfer, A. Rahman, J. Noe, Q. Zhang, and V. Subbiah
973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC, M. C. Garassino, Shirish M. Gadgeel, G. Speranza, E. Felip, E. Esteban Gonzalez, M. Domine Gomez, M. J. Hochmair, S. F. Powell, H. Bischoff, N. Peled, F. Grossi, R. Jennens, M. Reck, R. Hui, E. B. Garon, T. Kurata, J. E. Gray, P. O. Schwarzenberger, E. Jensen, and D. Rodriguez Abreu
DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes, Laura Graham, Edward Green, Joseph J. Park, Olesia Kellezi, Clara Hwang, Pedro C. Barata, Mehmet A. Bilen, Deepak Kilari, Melissa Clingerman, Abhishek Tripathi, Matthew Labriola, Shoshana Rothstein, Rohan Garje, Vadim S. Koshkin, Vaibhav G. Patel, Tanya B. Dorff, Andrew J. Armstrong, Rana R. McKay, Ajjai S. Alva, and Michael T. Schweizer
The role of African Duffy-null allele related inflammation on the tumor microenvironment, Yanira Guerra, Rachel Martini, Jessica Bensenhaver, Yalei Chen, Joseph K. Oppong, Ishmael Kyei, Frances S. Aitpillah, Michael O. Adinku, Joseph K. Oppong, Ernest K. Adjei, Aisha Jibril, Baffour Awuah, Mahteme Bekele, Engida Abebe, Kwasi Ankomah, Ernest B. Osei-Bonsu, Kofi K. Gyan, Clayton Yates, Kim Blenman, Olivier Elemento, Lisa Newman, and Melissa B. Davis
A prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19, S. Halabi, B. Luo, H. Dzimitrowicz, Clara Hwang, T. M. Wise-Draper, C. Labaki, R. R. McKay, E. Ruiz, C. Rangel-Escareño, D. Farmakiotis, E. A. Griffiths, C. T. Jani, M. Accordino, C. Friese, E. Wulff-Burchfield, M. Puc, P. Yu, U. Topaloglu, S. Mishra, and J. Warner
790MO Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel), O. Hamid, Amy Weise, T. M. Kim, M. A. Mckean, N. J. Lakhani, J. Kaczmar, K. P. Papadopoulos, S. Chen, J. Mani, V. Jankovic, G. Kroog, T. Sims, I. Lowy, and G. Gullo
Phase 1 study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, plus cemiplimab in advanced melanoma, O. Hamid, Amy Weise, T. M. Kim, M. McKean, N. J. Lakhani, J. Kaczmar, K. P. Papadopoulos, S. Chen, J. Mani, V. Jankovic, G. Kroog, T. Sims, I. Lowy, and G. Gullo
Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study, Vadim S. Koshkin, Guru P. Sonpavde, false Hwang, Begona Mellado, Gareth Tomlinson, Masashi Shimura, Michael J. Chisamore, Maciej Gil, and Yohann Loriot
OA06.06 Impact of Systemic Anti-cancer Treatments on Outcomes of COVID-19 in Patients with Thoracic Cancers: CCC19 Registry Analysis, A. Kulkarni, C. Hennessy, G. Wislon, V. Ramesh, Clara Hwang, A. Joy, Z. Bakouny, H. Khan, D. Vilar-Compte, R. McKay, C. Jani, J. W. Riess, M. Puc, A. Kasi, S. Berg, D. R. Castillo, B. Hayes-Lattin, W. Hosmer, D. Flora, S. Mishra, B. French, J. Warner, G. Lopes, S. Peters, and N. Duma
43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy, T. A. Leal, D. Berz, Igor I. Rybkin, W. T. Iams, D. Bruno, C. Blakely, A. Spira, M. Patel, D. M. Waterhouse, D. Richards, A. Pham, R. Jotte, E. B. Garon, D. S. Hong, R. Shazer, X. Yan, L. Latven, and K. He
The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT), N. Ohri, S. Jolly, B. T. Cooper, R. Kabarriti, W. R. Bodner III, J. Klein, S. Viswanathan, R. Kaufman, E. Shum, J. K. Sabari, H. Cheng, R. Gucalp, E. Castellucci, A. Qin, Shirish M. Gadgeel, and B. Halmos
Sentinel Lymph Node Positivity in Clinically Node Negative Breast Cancer Patients After Neoadjuvant Chemotherapy: Opportunities to Defer Intraoperative Frozen Section Analysis, Omar Qutob, Jessica Bensenhaver, Laura L. Susick, Lindsay Petersen, Anna Lehrberg, Fallon Dimaano, and Theresa Schwartz
Disparity Outcomes in Patients Undergoing Pancreas Surgery at an Urban Tertiary Care Center, Mariam A. Saad, Kendyll J. Gartrelle, Rupen Shah, Julie Clark, Kyra Langley, Erin Field, Christopher P. Steffes, and David S. Kwon
A single-center analysis of 30- and 90-day post-pancreatectomy complications in patients undergoing neoadjuvant radiation with EBRT versus MRI-guided SBRT, Mariam Saad, Julie Clark, Rupen A. Shah, Farzan Siddiqui, Parag J. Parikh, Kendyll J. Gartrelle, Abdul Kader Natour, Gazala Khan, and David Kwon
Evaluation of Practice Patterns and Outcomes after Implementing SMART for Pancreatic Cancer, Eric Schaff, Parag J. Parikh, Pin Li, Rupen Shah, Gazala Khan, Farzan Siddiqui, Benjamin Movsas, and David Kwon
Update on a pilot study: Flumeltbi peripheral blood HLAhaploidentical stem cell transplantation with post-transplant cyclophosphamide and bortezomib (Cy2Bor3), Sowjanya Vuyyala, Edward Peres, Klodiana Neme, Nancy Mikulandric, Susan M. Wautelet, Danielle L. Pelland, Nada Zagar, Mary A. Trapp, Scott R. Rohrer, Elizabeth A. Henne, Sarah Szymanski, Josephine Emole, Muneer H. Abidi, and Shatha Farhan
Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts), Zeynep B. Zengin, Nicholas Henderson, Joseph J. Park, Alicia Ali, Clara Hwang, Pedro C. Barata, Mehmet A. Bilen, Laura Graham, Deepak Kilari, Abhishek Tripathi, Matthew Labriola, Shoshana Rothstein, Rohan Garje, Vadim S. Koshkin, Vaibhav G. Patel, Michael T. Schweizer, Andrew J. Armstrong, Rana R. McKay, Ajjai S. Alva, and Tanya B. Dorff
Submissions from 2021
Satisfaction of hem/onc patients with video visits during the COVID-19 pandemic at a tertiary care center in Michigan, Fawzi Abu Rous, Pin Li, Mohamed Elgamal, Hussna Abunafessa, Rebecca Chacko, Sowjanya Vuyyala, Yaser Alkhatib, and Philip Kuriakose
O-15 Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup, J Ajani, F El Hajbi, D Cunningham, M Alsina, P Thuss-Patience, G Scagliotti, M Van den Eynde, Igor Rybkin, L Shen, K Kato, S Kim, S D'Alonzo, W Yu, A Tao, and E Van Cutsem
1317P Renal toxicity in black patients with non-squamous non-small cell lung cancer treated with combination platinum-pemetrexed-pembrolizumab therapy, Nino Balanchivadze, Zeinab Nasser, Muhammad Shahid, Cortney McKay, Pin Li, Ryann Sohaney, and Shirish M. Gadgeel
P08.04 Comparative Clinical Outcomes Between EGFR Exon20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors, L Bazhenova, N Girard, A Minchom, S Ou, Shirish M. Gadgeel, J M. Trigo, S Viteri, A Londhe, P Mahadevia, and J Bauml
A phase 1b/2 umbrella study of anti-PD-1 sasanlimab in combination with other therapies for patients with stage IIIb/Iv nonsmall cell lung cancer (NSCLC): The landscape 1011 trial in progress, Michael Boyer, Sandip Patel, Thomas Marron, Nick Pavlakis, Sagun Parakh, Shirish Gadgeel, Michael Shafique, Robert Hoyer, D. Ross Camidge, Charles Farber, Ranee Mehra, Tarek Mekhail, Prunella Blinman, Karey Kowalski, Craig Davis, Dmitri Pavlov, Nayra Gad, and Erminia Massarelli
Molecular Biomarker Testing and Targeted Therapy Patterns in Patients with Acute Myelogenous Leukemia (AML) in Community Health Systems in the United States: A Real-World Data Analysis, Francesca Coutinho, Zartash Gul, Anna B. Berry, Michael A. Thompson, Christopher A. Willner, Sowjanya Vuyyala, Haley McCracken, Katherine Geverd, Jeanna Wallenta Law, Frank M. Wolf, Thomas D. Brown, and Philip Kuriakose
1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C, R Dziadziuszko, S Peters, Shirish M. Gadgeel, S M. Shagan, E Felip, A Morabito, P Cheema, M C. Dols, Z Andric, C H. Barrios, M Yamaguchi, E Dansin, P Danchaivijitr, M Johnson, S Novello, D R. Gandara, E Schleifman, J Wang, and T S.K. Mok
1632P At home androgen deprivation therapy for patients with prostate cancer during the COVID-19 pandemic. One center experience, T Esakia, T Melkadze, K Tsiklauri, E Mariamidze, S Tsitsilashvili, N Otkhozoria, M Abuladze, N Jokhadze, and Nino Balanchivadze
Pemetrexed and platinum plus pembrolizumab in patients with metastatic non-squamous non-small cell lung cancer by tumor burden at baseline: A post-hoc efficacy analysis of KEYNOTE-189, Shirish Gadgeel, Jhanelle Grey, Maria Teresa Rizzo, Patrick Peterson, Jongseok Kim, and Delvys Rodríguez-Abreu
P10.03 Pembrolizumab With or Without Chemotherapy for Advanced Lung Cancer: A Real-World Analysis of Key Prognostic Factors, Shirish M. Gadgeel, M Izano, C Sweetnam, Igor Rybkin, M Hendawi, J Weese, A Patel, D Reding, J Treisman, A Stafford, F Wolf, C Zhang, and T Brown
MO01.38 Registrational Dataset from the Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion+ Non-Small-Cell Lung Cancer (NSCLC), J F. Gainor, G Curigliano, D W. Kim, D H. Lee, B Besse, C S. Baik, R C. Doebele, P Cassier, G Lopes, D SW Tan, E Garralda, L Paz-Ares, B C. Cho, Shirish M. Gadgeel, M Thomas, S V. Liu, C Clifford, H Zhang, C D. Turner, and V Subbiah
KRAS mutations in patients with nonsquamous non-small-cell lung cancer: Prevalence and relationship with PD-l1 expression, tumor mutation burden and smoking status, Marina C. Garassino, Delvys Rodriguez-Abreu, Shirish M. Gadgeel, Dariusz M. Kowalski, Kazuo Kasahara, Enriqueta Felip, Yi-Long Wu, Gilberto de Castro, Byoung Chul Cho, Hande Z. Turna, Hidehito Horinouchi, Martin Reck, Rina Hui, Edward B. Garon, Michael Boyer, Tony S. K Mok, Gilberto Lopes, Julie Kobie, Yongjin Li, Mark A. Ayers, Razvan Cristescu, Bin Zhao, M. Catherine Pietanza, and Roy S. Herbst
MA04.07 Comparative Clinical Outcomes for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutations and Common EGFR Mutations, N Girard, L Bazhenova, A Minchom, S Ou, Shirish M. Gadgeel, J Trigo, S Viteri, G Li, P Mahadevia, A Londhe, D Backenroth, T Li, and J M. Bauml
61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199, J N. Graff, S Tagawa, C Hoimes, W Gerritsen, U N. Vaishampayan, T Elliott, Clara Hwang, A J.T. Tije, A G. Omlin, R S. McDermott, R De Wit, P Qiu, C Poehlein, J Kim, L Suttner, R Cristescu, M J. Marton, C Schloss, J S. de Bono, and E S. Antonarakis
Phase 1 trial of SQ3370 in solid tumors, Alexander Guminski, Ding Wang, Nam Bui, Vivek Bhadri, Madhawa De Silva, Robert Steffner, Nathan A. Yee, Sangeetha Srinivasan, Jose M. Mejia Oneto, M. Wayne Saville, and Vivek Subbiah
Creating PDXs from continental African breast tumors: Addressing racial inequity through science, Evelyn M. Jiagge, Tahra K. Suhan, Jessica M. Bensenhaver, Michele Dziubinski, Joseph K. Oppong, Francis Aitpillah, Awuah Baffour, John D. Carpten, Lisa A. Newman, Sofia D. Merajver, and Max S. Wicha
P10.04 Immunotherapy-Treated Non-Small Cell Lung Cancer Patients With Sensitizing Gene Alterations: A Real World Survival Analysis, Leila Khaddour, C Zhang, Faria Ali, Shirish M. Gadgeel, E Tadesse, M Thompson, D Reding, J Treisman, A Berry, M Izano, C Sweetnam, A Stafford, F Wolf, T Brown, and Igor Rybkin
A Phase 1 Dose Escalation Study of Dual PI3K and DNA PK Inhibitor, BR101801 in Adult Patients with Advanced Hematologic Malignancies, Tae Min Kim, Dok Hyun Yoon, Ahmad Mattour, Jorge M. Chaves, Emily Curran, Yoon Kyung Jeon, Bong-Seog Kim, and Seok Jin Kim
Combining enadenotucirev and nivolumab increased tumour immune cell infiltration/ activation in patients with microsatellitestable/ instability-low metastatic colorectal cancer in a phase 1 study, David Krige, Marwan Fakih, Lee Rosen, Ding Wang, Wael Harb, Hani Babiker, Jordan Berlin, Gianfranco Di Genova, David Miles, Mark Powell, Minesh Patel, Jo Carter, Richard Brown, and Tom Lillie
CT-423: Neuropsychiatric Disorders in Hospitalized Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma, O Lawal, O Lupak, I Udo, and Josephine Emole
1191O MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy, T A. Leal, D Berz, Igor I. Rybkin, W T. Iams, D Bruno, C Blakely, A Spira, M R. Patel, D M. Waterhouse, D Richards, A Pham, R Jotte, E B. Garon, D Hong, R Shazer, X Yan, L Latven, and K He
Phase 1 study of mRNA-2752, A lipid nanoparticle encapsulating mRNAs encoding human OX40L/IL-23/IL-36G, for intratumoral (ITU) injection +/-durvalumab in advanced solid tumors and lymphoma, Manish Patel, Antonio Jimeno, Ding Wang, Salomon Stemmer, Todd Bauer, Randy Sweis, Ravit Geva, Shivaani Kummar, Patrick Reagan, Ruth Perets, Patricia LoRusso, Shilpa Gupta, Sima Zacharek, Andressa Laino, Oleg Milberg, Josh Frederick, Sheryl Chen, Stephanie Pascarella, William Randolph, Praveen Aanur, Lisa Johansen, Khanh Do, Robert Meehan, and Ryan Sullivan
961MO Safety, efficacy, immunogenicity of arenavirus-based vectors HB-201 and HB-202 in patients with HPV16+ cancers, M R. Posner, A L. Ho, J Niu, L Nabell, R S. Leidner, J Nieva, D L. Richardson, A T. Pearson, Ding Wang, K Chung, D R. Adkins, A Pimentel, S Wong, C Lacobucci, X Qing, K Katchar, K Schlienger, I Matushansky, S Fu, and D G. Pfister
KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non-small cell lung cancer (NSCLC) harboring KRASG12C mutation, G J. Riely, S H.I. Ou, Igor Rybkin, A Spira, K Papadopoulos, J K. Sabari, M Johnson, R S. Heist, L Bazhenova, M Barve, J M. Pacheco, K Velastegui, C Cilliers, P Olson, J G. Christensen, T Kheoh, R C. Chao, and P A. Janne
Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with pembrolizumab (pembro) in patients (pts) with HER2-expressing advanced solid tumors, Manish R. Sharma, Richard D. Carvajal, Daniel Catenacci, Leisha A. Emens, Glenn J. Hanna, Dejan Juric, Yoon-Koo Kang, Jeeyun Lee, Keun-Wook Lee, Bob T. Li, Kathleen Moore, Mark D. Pegram, Paula R. Pohlmann, Drew Rasco, Alexander Spira, Arielle L. Heeke, Ding Wang, Lawrence Garbo, Sudhir Manda, Jasgit Sachdev, Shelley E. Ackerman, Heidi LeBlanc, David Dornan, Marcin Kowanetz, Michael N. Alonso, Amreen Husain, Edith A. Perez, and Ecaterina I. Dumbrava
Preliminary results from a phase I/II study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors, M R. Sharma, R D. Carvajal, G J. Hanna, Y K. Kang, J Lee, K W. Lee, B T. Li, K N. Moore, M Pegram, D Rasco, A Spira, Ding Wang, B A. Weinberg, M Alonso, L Fang, A Husain, M Kowanetz, E A. Perez, and E I. Dumbrava
OA17.04 The Global Impact of COVID-19 on Telehealth and Care for Persons With Thoracic Cancers, M Smeltzer, B Bunn, Y S. Choi, L Coate, J Corona-Cruz, A Drilon, N Duma, M Edelman, M J. Fidler, Shirish M. Gadgeel, Y Goto, R Herbst, M Hesdorffer, K Higgins, B Labdi, T Leal, S Liu, J Mazotti, S Novello, S Patel, S Popat, R Ramirez, K Reckamp, N Reguart, R Soo, A Tan, J Wolf, S Yano, B Stiles, and A Baird
P77.04 PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors, D R. Spigel, D Rodríguez-Abreu, F Cappuzzo, V Velcheti, A K. Ganti, D Johnson, R Govindan, S Antonia, B Besse, M Altan, M Edelman, S Ramalingam, E Felip, Shirish M. Gadgeel, O Juan-Vidal, A Gupta, S Currie, W Lin, M Tagliaferri, and M Reck
MO01.33 CRESTONE – Clinical Study of REsponse to Seribantumab in Tumors with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210), D Spigel, S N. Waqar, M E. Burkard, J J. Lin, Y K. Chae, M A. Socinski, Shirish M. Gadgeel, K L. Reckamp, S M. Leland, D Plessinger, L Kunkel, J R. Bauman, G Otterson, B Halmos, Ou SH Ignatius, T Patil, Y Y. Elamin, and E S. Kim
Hyperhemolysis Syndrome in SCD Patient: Reminder of a Rare but Life-Threatening Complication of Blood Transfusion, Aroob Sweidan, Sowjanya Vuyyala, Peter Xie, Mohammad Alhyari, Vrushali Dabak, and Zaher K. Otrock
LUMINOS-102: PVSRIPO with or without immune checkpoint blockade in unresectable anti-PD-1 refractory melanoma, Ding Wang, C. Lance Cowey, Evan Pisick, John Kirkwood, Daniel Corum, Shannon R. Morris, Andrea T. Kelly, Jessica Sorrentino, Lori Mixson, Adam Dickinson, W. Garrett Nichols, and Yana G. Najjar
P78.05 Patterns of irAE During First Line Pembrolizumab for NSCLC: Incidence, Risk Factors, and Impact on Clinical Outcome, C Wood, G Lopez, L Zhao, M Li, N Surya, S Patel, M Grogan, E Bertino, P Shields, K He, D Carbone, G Otterson, C Presley, B Pannecouk, G Kalemkerian, B Schneider, Shirish M. Gadgeel, N Ramnath, D Owen, and A Qin
Submissions from 2020
A multicenter, open-label, dose-escalation, first-in-man study of MetAP2 inhibitor M8891 in patients with advanced solid tumours, M A. Carducci, Ding Wang, C Habermehl, M Bödding, F Rohdich, S Stinchi, O Karpenko, C Gimmi, and P LoRusso
Towards Evidence Based Practice: The American Radium Society (ARS) and American College of Radiology (ACR) Appropriate Use Guidelines on Radiation Therapy for Muscle-Invasive Bladder Cancer, T K. Dinh, T Mitin, K Hoffman, Clara Hwang, R J. Karnes, A Kishan, S Liauw, S Lloyd, L Potters, T Showalter, A Taira, N Vapiwala, N Zaorsky, A D'Amico, P Nguyen, and B Davis
Blood-based genomic profiling of advanced non-small cell lung cancer (aNSCLC) patients (pts) from blood first assay screening trial (BFAST) and comparison with real-world data (RWD), R Dziadziuszko, Q Zhang, X Li, S M. Paul, M Sugidono, S Mocci, A Kinkolykh, D S. Shames, V Archer, M S. Mathisen, D X. Jin, Shirish M. Gadgeel, S Peters, and T Mok
Prospective Randomized Study of Prophylactic Ciprofloxacin Versus Levofloxacin in Hematopoietic Stem Cell Transplant Patients: An Interim Report, Shatha Farhan, Georgiana Marusca, Michael Bazydlo, Klodiana Neme, Nancy Mikulandric, Josena K. Stephen, Nada Kortam, R Mayur, Danielle L. Pelland, Nada Zagar, Mary A. Trapp, Elizabeth A. Henne, Scott R. Rohrer, Sarah Szymanski, Josephine Emole, Edward Peres, and Nalini Janakiraman
Blood first assay screening trial (BFAST) in patients (pts) with 1L NSCLC: ALK+ cohort updated biomarker analyses, Shirish M. Gadgeel, M Yan, S M. Paul, M Mathisen, S Mocci, Z J. Assaf, R Patel, E S. Sokol, T Mok, S Peters, L Paz-Ares, and R Dziadziuszko
Racial Disparities Among Pancreatic Adenocarcinoma Patients: A Retrospective Survival Analysis of Non-Metastatic Pancreatic Cancer Patients, Kendyll J. Gartrelle, Eric M. Schaff, Celina Kirsch, David Kwon, Munther Ajlouni, Gazala Khan, Rupen Shah, Irina Dobrosotskaya, Parag J. Parikh, and Farzan Siddiqui
Does Age Impact Outcomes of Oropharyngeal squamous cell carcinoma?, Ahmed I. Ghanem, Matthew Schymick, Souheyla Bachiri, Remonda M. Khalil, Charlotte Burmeister, Jawad Sheqwara, Steven S. Chang, Tamer Ghanem, and Farzan Siddiqui
Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5, J N. Graff, E S. Antonarakis, C J. Hoimes, S T. Tagawa, Clara Hwang, D Kilari, A J. Ten Tije, A G. Omlin, R S. McDermott, U N. Vaishampayan, A Elliott, H Wu, J Kim, C Schloss, and J S. De Bono
Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate, E P. Hamilton, M A. Barve, A W. Tolcher, J Buscema, K P. Papadopoulos, C Zarwan, C K. Anderson, D Doroshow, Ding Wang, D Huebner, V M. Jansen, D Jarlenski, R Mosher, J Kaufman, K N. Moore, and D L. Richardson
American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC, Kristin A. Higgins, Charles B. Simone, Arya Amini, Indrin J. Chetty, Jessica Donington, Martin J. Edelman, Stephen G. Chun, Larry L. Kestin, Benjamin Movsas, George B. Rodrigues, Kenneth E. Rosenzweig, Ben J. Slotman, Igor Rybkin, Andrea Wolf, and Joe Y. Chang
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation, P A. Jänne, Igor I. Rybkin, A I. Spira, G J. Riely, K P. Papadopoulos, J K. Sabari, M L. Johnson, R S. Heist, L Bazhenova, M Barve, J M. Pacheco, T A. Leal, K Velastegui, C Cornelius, P Olson, J G. Christensen, T Kheoh, R C. Chao, and S H.I. Ou
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation, Melissa L. Johnson, Sai-Hong Ignatius Ou, Minal Barve, Igor I. Rybkin, Kyriakos P. Papadopoulos, Ticiana A. Leal, Karen Velastegui, James G. Christensen, Thian Kheoh, Richard C. Chao, and Jared Weiss
Clinical outcomes of patient migration in locally advanced rectal cancer from community cancer centers: An analysis of the National Cancer Database, R Kumar, S Bhandari, P Ngo, Sukhpreet RK Singh, S J. Malapati, and A Rojan
Progressive hyperleukocytosis associates with differential syndrome in acute promyelocytic leukemia patients treated with all-trans retinoic acid and arsenic trioxide, Qunfang Li and Yue Guo
4-year survival in randomised phase II (POPLAR) and phase III (OAK) studies of atezolizumab (atezo) vs docetaxel (doc) in pre-treated NSCLC, J Mazieres, A Rittmeyer, Shirish M. Gadgeel, T Hida, D Gandara, D Cortinovis, F Barlesi, W Yu, C Matheny, M Ballinger, and K Park
KEYNOTE-199 cohorts 4 and 5: Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC), R McDermott, J N. Graff, E S. Antonarakis, C J. Hoimes, S T. Tagawa, Clara Hwang, D Kilari, A JT Tije, A Omlin, U N. Vaishampayan, A Elliott, H Wu, J Kim, C Schloss, and J S. De Bono
Phase Ib/II study of ibrutinib (ibr) in combination with cetuximab (cetux) in patients (pts) with previously treated metastatic colorectal cancer (mCRC), D Y. Oh, T Arkenau, K W. Lee, M Alsina, F M. Marti, I J. Chung, W Saif, Ding Wang, P O'Dwyer, I Chau, M A. Lee, E Chong, J Hilger-Rolfe, G Cole, and S Y. Kim
KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update, A G. Omlin, J N. Graff, C J. Hoimes, S T. Tagawa, Clara Hwang, D Kilari, A J. Ten Tije, R McDermott, U N. Vaishampayan, T Elliott, W R. Gerritsen, H Wu, J Kim, C Schloss, J S. de Bono, and E S. Antonarakis
Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression, S I. Ou, B Solomon, A Shaw, Shirish M. Gadgeel, B Besse, R A. Soo, A Abbattista, H Thurm, F Toffalorio, R J. Wiltshire, and A Bearz
Tissue sound speed is more strongly associated with breast cancer risk than mammographic percent density: A comparative case-control study, M Sak, N Duric, R Pfeiffer, M Sherman, P Littrup, M Simon, D Gorski, T Albrecht, Haythem Y. Ali, R Brem, S Fan, and G Gierach
Magnetic Resonance Guided Stereotactic Ablative Radiation Therapy Versus External Beam RT with Chemotherapy For Pancreatic Cancer: Single Institution Toxicity Analysis Of Patients Treated In An Urban Academic Center, Eric Schaff, Kendyll J. Gartrelle, Celina Kirsch, Farzan Siddiqui, Munther Ajlouni, Jadranka Dragovic, Ibrahim Aref, Mira M. Shah, David Kwon, Irina Dobrosotskaya, Rupen Shah, Gazala Khan, and Parag J. Parikh
A Phase 1b/2a Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Nanogenistein in Combination with Chemoradiotherapy for Non-small Cell Lung Cancer, C B. Simone, Benjamin Movsas, E M. Gore, P Mohindra, Z Vujaskovic, Ding Wang, Munther Ajlouni, S Menon, J Thompson, Stephen L. Brown, M Kurman, J C. Dykstra, L Rillo, M Ingram, A Serebrenik, and M D. Kaytor
Initial results of a phase I study of MK-4830, a first-in-class anti–immunoglobulin-like transcript 4 (ILT4) myeloid-specific antibody in patients (pts) with advanced solid tumours, L L. Siu, Ding Wang, J Hilton, R Geva, D Rasco, A K. Abraham, J F. Markensohn, L Suttner, S Siddiqi, R A. Altura, and C Maurice-Dror
Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199, U N. Vaishampayan, T Elliott, A G. Omlin, J N. Graff, C J. Hoimes, S T. Tagawa, Clara Hwang, D Kilari, A JT Tije, R S. McDermott, W R. Gerritsen, H Wu, J Kim, S Schloss, J S. de Bono, and E S. Antonarakis
